Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Sirnaomics Out-Licenses siRNA Influenza Vaccine Candidate to Walvax

publication date: Apr 29, 2021

Sirnaomics Biopharma (Suzhou) out-licensed Greater China rights for its anti-influenza siRNA therapeutic candidate to Walvax Biotech, a Kunming vaccine company. Walvax made a $6.4 million upfront payment and will also be responsible for undisclosed milestone and royalty payments. To develop STP702, Sirnaomics identified potent siRNA sequences that target highly conserved regions of influenza viral genes, a combination that exhibited broad anti-influenza activity. The nanoparticle-enhanced siRNA delivery also improves the candidate's anti-influenza activity, which is higher than marketed flu products, the company said. More details....

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital